CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 50 enrolled
Drug / intervention
BBI-4000, 15% +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02682238
NCT02682238Phase 2Completed

A Multicenter, Randomized, Double-Blinded, Vehicle-Controlled Study to Evaluate the Safety and Local Tolerability of Topically Applied BBI-4000 (Sofpironium Bromide) 15% Gel in Subjects With Palmar Hyperhidrosis

Botanix Pharmaceuticals·interventional·Posted Feb 15, 2016·Updated May 19, 2023

In Brief

A Phase 2 clinical trial evaluating BBI-4000, 15% and Vehicle gel for Hyperhidrosis. Completed, enrolled 50 participants across 5 sites.

Detailed Summary

To assess the safety and local tolerability of BBI-4000 15% gel compared with vehicle (placebo) when applied topically once daily in subjects with palmar hyperhidrosis.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHyperhidrosis
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedFeb 15, 2016
Enrollment StartMar 8, 2016
Primary CompletionJul 14, 2016
Study CompletionOct 4, 2016
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 10.4 years ago

Interventions

BBI-4000, 15%drug

Vehicle gelother